# AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

> **NCT01741194** · PHASE2,PHASE3 · COMPLETED · sponsor: **Cerecin** · enrollment: 418 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** AC-1204
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01741194
- **Lead sponsor:** Cerecin
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2016-10-24
- **Final completion:** 2017-04-14
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2021-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01741194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01741194, "AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01741194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*